AstraZeneca PLC (AZN) Financials
Key financial figures for AstraZeneca PLC (Q3 2026).
Q3 2026 Total Revenue of $16,209m rose 7% (7% at CER) and Core EPS of $2.79 rose 17% (19% CER); FY 2026 guidance was reconfirmed. Q3 2026 Total Revenue was $16,209m, up 7% actual and 7% at constant exchange rates (CER) from $15,191m in Q3 2025. Product Sales were $15,066m (+5%) and Alliance Revenue $1,107m (+36%). Reported EPS was $2.02 (Q3 2025: $1.64, +23%) and Core EPS was $2.79 (+17% actual, +19% CER). Core operating margin was 36% (+3pp actual, +4pp CER) on Core operating profit of $5,855m. Oncology Total Revenue was $7,765m (+17%), led by Imfinzi $1,990m (+24%), Tagrisso $2,087m (+12%), Enhertu $969m (+36%) and Calquence $1,065m (+16%). Rare Disease was $2,633m (+9%). On the outlook: Reconfirmed FY 2026 guidance at CER (based on average FX rates through 2025): Total Revenue expected to increase by a mid-to-high single-digit percentage and Core EPS by a low double-digit percentage, with a Core tax rate of 18-22%; guidance is unchanged from the prior announcement. If FX rates for October to December 2026 stay at September 2026 averages, FY Total Revenue would see a low single-digit percentage positive FX impact versus CER and Core EPS growth would be broadly similar to CER growth (both unchanged). Figures are for Q3 2026, as AstraZeneca PLC reported them.
- Revenue
- $16.0B
- Net Income
- $3.1B
- EPS
- $1.98
- Total Assets
- $119.7B
- Operating Cash Flow
- $4.7B
Recent quarters
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| Q3 FY2026 | $16.0B | $3.1B | $1.97 | 27.02% | $4.0B |
| Q2 FY2026 | $15.4B | $2.5B | $1.59 | 20.57% | $2.1B |
| Q1 FY2026 | $15.3B | $3.1B | $1.97 | 27.77% | $1.8B |
| Q4 FY2025 | $15.5B | $2.3B | $1.48 | 19.21% | $1.4B |
| Q3 FY2025 | $15.2B | $2.5B | $1.62 | 23.59% | $3.4B |
Recent fiscal years
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| FY2025 | $58.7B | $10.3B | $6.54 | 23.4% | $8.7B |
| FY2024 | $54.1B | $7.0B | $4.50 | 18.5% | $7.3B |
| FY2023 | $45.8B | $6.0B | $3.81 | 17.88% | $6.6B |
Frequently asked questions
What was AstraZeneca PLC's revenue last quarter?
AstraZeneca PLC reported revenue of $15.99 billion for Q3 FY2026, up 5.3% from the same period a year earlier.
Is AstraZeneca PLC profitable?
Yes. AstraZeneca PLC reported net income of $3.08 billion for Q3 FY2026, a net margin of 19.23% on revenue.
How has AstraZeneca PLC's margin trended?
Operating margin was 27.02% in Q3 FY2026, compared with 23.59% in the same period a year earlier. The quarter by quarter series is on the SentiSense financials page.
How much free cash flow did AstraZeneca PLC generate?
AstraZeneca PLC generated free cash flow of $3.99 billion in Q3 FY2026, after capital expenditure.
Full income statement, balance sheet and cash flow for AstraZeneca PLC on SentiSense, with up to forty quarters and twenty fiscal years of history.